Rui R He, Zacharia Nayer, Matthew Hogan, Raymund S Cuevo, Kimberly Woodward, David Heyer, Christine A Curtis, Jess F Peterson
{"title":"免疫治疗- (blinatumumab -)相关谱系开关KMT2A/AFF1重排B淋巴母细胞白血病为急性髓系白血病/髓系肉瘤，随后为B/髓系混合表型急性白血病","authors":"Rui R He, Zacharia Nayer, Matthew Hogan, Raymund S Cuevo, Kimberly Woodward, David Heyer, Christine A Curtis, Jess F Peterson","doi":"10.1155/2019/7394619","DOIUrl":null,"url":null,"abstract":"<p><p>The presence of <i>KMT2A/AFF1</i> rearrangement in B-lymphoblastic leukemia (B-ALL) is an independent poor prognostic factor and has been associated with higher rate of treatment failure and higher risk of linage switch under therapy. Blinatumomab has shown promising therapeutic results in refractory or relapsed B-ALL; however, it has potential risk of inducing lineage switch, especially in <i>KMT2A/AFF1</i> rearranged B-ALL into acute myeloid leukemia and/or myeloid sarcoma. We report a 40-year-old female with <i>KMT2A/AFF1</i>-rearranged B-ALL that was refractory to conventional chemotherapy. Following administration of blinatumomab, she developed a breast mass proven to be myeloid sarcoma, in addition to bone marrow involvement by AML. Approximately six weeks after cessation of blinatumomab, a repeat bone marrow examination revealed B/myeloid MPAL.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2019 ","pages":"7394619"},"PeriodicalIF":0.7000,"publicationDate":"2019-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/7394619","citationCount":"20","resultStr":"{\"title\":\"Immunotherapy- (Blinatumomab-) Related Lineage Switch of <i>KMT2A/AFF1</i> Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia.\",\"authors\":\"Rui R He, Zacharia Nayer, Matthew Hogan, Raymund S Cuevo, Kimberly Woodward, David Heyer, Christine A Curtis, Jess F Peterson\",\"doi\":\"10.1155/2019/7394619\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The presence of <i>KMT2A/AFF1</i> rearrangement in B-lymphoblastic leukemia (B-ALL) is an independent poor prognostic factor and has been associated with higher rate of treatment failure and higher risk of linage switch under therapy. Blinatumomab has shown promising therapeutic results in refractory or relapsed B-ALL; however, it has potential risk of inducing lineage switch, especially in <i>KMT2A/AFF1</i> rearranged B-ALL into acute myeloid leukemia and/or myeloid sarcoma. We report a 40-year-old female with <i>KMT2A/AFF1</i>-rearranged B-ALL that was refractory to conventional chemotherapy. Following administration of blinatumomab, she developed a breast mass proven to be myeloid sarcoma, in addition to bone marrow involvement by AML. Approximately six weeks after cessation of blinatumomab, a repeat bone marrow examination revealed B/myeloid MPAL.</p>\",\"PeriodicalId\":46307,\"journal\":{\"name\":\"Case Reports in Hematology\",\"volume\":\"2019 \",\"pages\":\"7394619\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2019-12-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2019/7394619\",\"citationCount\":\"20\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2019/7394619\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2019/7394619","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia.
The presence of KMT2A/AFF1 rearrangement in B-lymphoblastic leukemia (B-ALL) is an independent poor prognostic factor and has been associated with higher rate of treatment failure and higher risk of linage switch under therapy. Blinatumomab has shown promising therapeutic results in refractory or relapsed B-ALL; however, it has potential risk of inducing lineage switch, especially in KMT2A/AFF1 rearranged B-ALL into acute myeloid leukemia and/or myeloid sarcoma. We report a 40-year-old female with KMT2A/AFF1-rearranged B-ALL that was refractory to conventional chemotherapy. Following administration of blinatumomab, she developed a breast mass proven to be myeloid sarcoma, in addition to bone marrow involvement by AML. Approximately six weeks after cessation of blinatumomab, a repeat bone marrow examination revealed B/myeloid MPAL.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
